Terms: = Lung cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
97 results:
1. Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.
Luo YH; Shen CI; Chiang CL; Huang HC; Chen YM
Front Immunol; 2024; 15():1269253. PubMed ID: 38343550
[TBL] [Abstract] [Full Text] [Related]
2. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model.
Hernández-Aceves JA; Cervantes-Torres J; Torres-García D; Zuñiga-Flores FJ; Patiño-Chávez OJ; Peña Agudelo JA; Aguayo-Flores JE; Garfias Y; Montero-León L; Romero-Romero L; Pérez-Torres A; Fragoso G; Sciutto E
Cancer Immunol Immunother; 2023 Nov; 72(11):3825-3838. PubMed ID: 37736849
[TBL] [Abstract] [Full Text] [Related]
5. The effect of gender on the clinical outcome of pd-1/PD-L1 inhibitor in advanced lung cancer patients.
Wu B; Sun C; Sun X; Li X
Medicine (Baltimore); 2023 Aug; 102(34):e34849. PubMed ID: 37653772
[TBL] [Abstract] [Full Text] [Related]
6. Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-pd-1 checkpoint blockade in non-small cell lung cancer.
Kudling TV; Clubb JHA; Pakola S; Quixabeira DCA; Lähdeniemi IAK; Heiniö C; Arias V; Havunen R; Cervera-Carrascon V; Santos JM; Sutinen E; Räsänen J; Borenius K; Mäyränpää MI; Aaltonen E; Sorsa S; Hemminki O; Kanerva A; Verschuren EW; Ilonen I; Hemminki A
Oncoimmunology; 2023; 12(1):2241710. PubMed ID: 37546696
[TBL] [Abstract] [Full Text] [Related]
7. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-pd-1/PD-L1 blockade therapy.
Inoue Y; Inui N; Karayama M; Asada K; Fujii M; Matsuura S; Uto T; Hashimoto D; Matsui T; Ikeda M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Suda T
Cancer Immunol Immunother; 2023 Aug; 72(8):2717-2728. PubMed ID: 37099186
[TBL] [Abstract] [Full Text] [Related]
8. Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China.
Ma Y; Shi H; Zhao G; Liu X; Cai J; Li G; Chen W; Lei Y; Ye L; Fu C; Zhao L; Zhou Y; Huang Y
Front Immunol; 2023; 14():1012166. PubMed ID: 36926333
[TBL] [Abstract] [Full Text] [Related]
9. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract] [Full Text] [Related]
10. Predictive biomarkers for pd-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.
So WV; Dejardin D; Rossmann E; Charo J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822668
[TBL] [Abstract] [Full Text] [Related]
11. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
[TBL] [Abstract] [Full Text] [Related]
12. Resistance to immune checkpoint inhibitors in advanced lung cancer: clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract] [Full Text] [Related]
13. The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?
Waissengrin B; Leshem Y; Taya M; Meiri D; Merimsky O; Shamai S; Wolf I; Rubinek T
Eur J Cancer; 2023 Feb; 180():52-61. PubMed ID: 36535195
[TBL] [Abstract] [Full Text] [Related]
14. Impact of Corticosteroids for IrAEs on the clinical outcome of Immunotherapy in Patients With NSCLC.
Shimomura K; Yamaguchi T; Oya Y; Uchida K; Murotani K
Anticancer Res; 2022 Dec; 42(12):5961-5969. PubMed ID: 36456164
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-pd-1 inhibitors.
Zhao X; Wu X; Yu H; Wang H; Sun S; Hu Z; Liu C; Zhang J; Shao Y; Wang J
Front Immunol; 2022; 13():1003581. PubMed ID: 36341410
[TBL] [Abstract] [Full Text] [Related]
16. Cisplatin and gemcitabine exert opposite effects on immunotherapy with pd-1 antibody in K-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
17. Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
Matsuzawa R; Morise M; Kinoshita F; Tanaka I; Koyama J; Kimura T; Kondoh Y; Tanaka T; Shima K; Hase T; Wakahara K; Ishii M; Hashimoto N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3885-3893. PubMed ID: 36006483
[TBL] [Abstract] [Full Text] [Related]
18. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
[TBL] [Abstract] [Full Text] [Related]
20. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
[Next]
